Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Recent health news includes EssilorLuxottica's new FDA-approved Nuance audio glasses, Baxter's CEO José Almeida retiring, Pfizer facing challenges with COVID-related revenue, WHO budget cuts amid U.S ...

European equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.50% to 1,356.26 on the S&P Europe Select ADR Index. From continental Europe, the gainers ...

Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

--"The 2025 forecast will command the most attention in the annual accounts," Hansen said. "The addition of production capacity will continue to be the guiding principle for the full-year forecast." ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

A collaboration between Nordita, The Nordic Institute for Theoretical Physics, hosted by Stockholm University and KTH and Google Quantum AI explores ...